PSMC2 knockdown exerts an anti-tumor role in nasopharyngeal carcinoma through regulating AKT signaling pathway.
Humans
Nasopharyngeal Carcinoma
/ pathology
Proto-Oncogene Proteins c-akt
/ metabolism
Cell Line, Tumor
Signal Transduction
Cell Proliferation
/ genetics
Nasopharyngeal Neoplasms
/ pathology
Cell Movement
/ genetics
Gene Expression Regulation, Neoplastic
ATPases Associated with Diverse Cellular Activities
/ genetics
Proteasome Endopeptidase Complex
/ metabolism
AKT pathway
Nasopharyngeal carcinoma
PSMC2
Journal
Cell cycle (Georgetown, Tex.)
ISSN: 1551-4005
Titre abrégé: Cell Cycle
Pays: United States
ID NLM: 101137841
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
pmc-release:
18
01
2025
medline:
22
1
2024
pubmed:
21
12
2023
entrez:
20
12
2023
Statut:
ppublish
Résumé
Nasopharyngeal carcinoma is a major public health problem in several countries, particularly in Southeast Asia and North Africa. However, the mechanism underlying the malignant biological behaviors of nasopharyngeal carcinoma is not fully clear. Our study intended to investigate the functional importance and molecular mechanism of proteasome 26 S subunit ATPase 2 (PSMC2) in the progression of nasopharyngeal carcinoma. We examined the expression of PSMC2 in both nasopharyngeal carcinoma tissues and normal healthy tissues using immunohistochemistry (IHC). Additionally, we conducted a series of cell experiments to verify the functional roles of PSMC2 and to explore the underlying pathway involved. The results revealed that PSMC2 was significantly upregulated in nasopharyngeal carcinoma tissues compared to normal tissues. Moreover, high PSMC2 was shown to closely correlate with the pathological stage and tumor infiltrate in nasopharyngeal carcinoma patients. Functionally, we observed a suppression of nasopharyngeal carcinoma progression upon knocking down PSMC2. This was evidenced by inhibited cell proliferation and migration
Identifiants
pubmed: 38123344
doi: 10.1080/15384101.2023.2293590
pmc: PMC10802197
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
PSMC2 protein, human
147416-58-8
ATPases Associated with Diverse Cellular Activities
EC 3.6.4.-
Proteasome Endopeptidase Complex
EC 3.4.25.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2381-2391Références
Oncogene. 2015 Apr 23;34(17):2156-66
pubmed: 25347742
Cell Death Discov. 2021 Oct 29;7(1):323
pubmed: 34716318
Nat Rev Clin Oncol. 2020 Jul;17(7):395-417
pubmed: 32203277
Cancer Lett. 2018 Jun 28;424:127-135
pubmed: 29596889
J Transl Med. 2022 Jun 8;20(1):264
pubmed: 35676661
Biosci Rep. 2021 Sep 30;41(9):
pubmed: 34515293
J Exp Clin Cancer Res. 2019 Nov 7;38(1):456
pubmed: 31699119
Cell. 2012 Aug 17;150(4):842-54
pubmed: 22901813
Ann Transl Med. 2019 Sep;7(18):470
pubmed: 31700906
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
Front Oncol. 2021 Mar 17;11:617621
pubmed: 33816248
Bioengineered. 2021 Dec;12(1):3398-3409
pubmed: 34224316
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
Cell Death Discov. 2021 Aug 19;7(1):217
pubmed: 34413286
Nat Commun. 2021 Sep 13;12(1):5404
pubmed: 34518526
Sci Rep. 2016 Nov 18;6:37443
pubmed: 27857231
Orphanet J Rare Dis. 2006 Jun 26;1:23
pubmed: 16800883
Oncotarget. 2017 Jan 3;8(1):933-953
pubmed: 27888613
Chemotherapy. 2019;64(3):146-154
pubmed: 31715603
Cancer Res. 2017 Jun 1;77(11):3092-3100
pubmed: 28377455
J Exp Clin Cancer Res. 2021 Dec 10;40(1):390
pubmed: 34893086
Eur J Histochem. 2021 Nov 16;65(4):
pubmed: 34783234
J Cancer. 2019 Aug 27;10(20):4939-4946
pubmed: 31598166
Proteomics. 2006 Jan;6(2):498-504
pubmed: 16317774
Sci Rep. 2019 Mar 12;9(1):4286
pubmed: 30862833
Cancer Res. 1999 Apr 1;59(7 Suppl):1693s-1700s
pubmed: 10197582
Lancet. 2016 Mar 5;387(10022):1012-1024
pubmed: 26321262